According to Emergent Research’s latest analysis, the global immune cytokines market is expected to reach USD 4,078.5 Million in 2028, with a revenue CAGR of 4.3% during the forecast period. Rising cancer cases worldwide and an aging population can be attributed to market revenue growth. Some of the key factors driving market revenue growth are the rising demand for advanced diagnostic procedures for cancer diagnosis and the increased use of monoclonal antibodies. Furthermore, new technological advancements in genetic sequencing techniques are contributing significantly to the global immune cytokines market’s growth.
From 2020 to 2028, the global immune cytokines market is expected to grow at a promising rate (forecast period). The unexpected surge in clinical trial investments to create new molecular structures for cancer treatments has provided a significant boost to the global immune cytokines market. As a result, more tolerable and safe molecular structures have been developed. Clinical testing for segments such as tumor necrosis factor, first-generation Interleukin-2, second-generation Interleukin-2, Interleukin-10, Interleukin-12, Interleukin-15, and Interferon is now a priority for players in the global immune cytokines market.
Cancer is one of the leading causes of death worldwide, with an estimated 0.6 million deaths in the United States alone in 2020. The World Health Organization predicts that the number of new cancer cases will rise by 70% globally over the next 20 years. Conventional treatment options, such as chemotherapy, radiation therapy, and surgery, are well known to have limited efficacy in late-stage cancers. Furthermore, the non-specific and highly toxic nature of traditional chemotherapy and radiation therapy has been shown to hurt patients’ quality of life. Immunotherapy has emerged as a versatile option among the emerging class of targeted anti-cancer therapies, demonstrating the ability to selectively target and eliminate tumor cells.
Key Highlights of the Report
Calquence by AstraZeneca was approved in Japan in January 2021. Calquence is a BTK inhibitor of the next generation that is used to treat relapsed or refractory chronic lymphocytic leukemia.
The FDA accepted Alkermes’ resubmission for the drug ALKS 3831 in December 2020. ALKS 3831 is a drug candidate being developed for the treatment of adults suffering from schizophrenia and bipolar 1 disorder.
North America had the largest revenue share in the global market in 2020 and is expected to grow at a much faster rate during the forecast period. This is due to significant investments in research and development of tumor detection techniques in the region. Furthermore, the presence of major market players in the region is fueling revenue growth in the North American market.
Alkermes Plc, AstraZeneca Plc, CytImmune Sciences, Cytune Pharma, Altor Bioscience Corporation, Apeiron Biologics AG, Paladin Labs, Teva Pharmaceutical Industries Ltd., Valor Biotherapeutics, and Targa Therapeutics Corporation are major players in the global immune cytokines market.
Emergen Research has segmented the global immune cytokines market based on disease indication, targeting site, and region:
- Disease Indication Outlook (Revenue, USD Million; 2018–2028)
- Tumor and Cancer
- Rheumatoid Arthritis
- Targeting Site Outlook (Revenue, USD Million; 2018–2028)
- Fat Muscle
- B and T Lymphocytes
- Bone Marrow Endothelium
- Regional Outlook (Revenue, USD Million; 2018–2028)
- North America
- the U.S.
- the U.K.
- Rest of Europe
- South Korea
- Rest of APAC
- Latin America
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of MEA
- North America
To get leading market solutions, Visit the Link